Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $19.7 million versus the consensus estimate of $18.36 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.